Home Featured Page 136

Featured

Latest

Approvals to Access: A Crude Schematic

Davis, Farchione and Colleagues Present FDA’s Psychedelic Drug Framework in NEJM

Psychedelic Philanthropy Is Entering Its Next Phase

Two New Zealand Psychiatrists Approved to Prescribe MDMA for PTSD

A Perspective on Providers: Scaling PAT in a Time of Therapist...

Making “Access” A Meaningful Part of Every Conversation about Psychedelic Therapy

Psychedelic Therapies: From Approvals to Access

Small Pharma Announces Update on Intellectual Property Portfolio with Two New...

Numinus Receives Clinical Trial Application Approval from Health Canada for Experiential...

PharmaTher Holdings Submits for FDA Orphan Drug Designation for Ketamine to...

Psyence and Eden Labs Announce Extraction and Product Development Collaboration

Silo Pharma Announces Stock Repurchase Program

FDA Grants Ehave Consent to Proceed With Its Clinical Study on...

Apex Labs Granted Approval for 294 Patient Take Home Psilocybin Clinical...

EDITOR PICKS

Approvals to Access: A Crude Schematic

Davis, Farchione and Colleagues Present FDA’s Psychedelic Drug Framework in NEJM

Psychedelic Philanthropy Is Entering Its Next Phase

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Approvals to Access: A Crude Schematic

Davis, Farchione and Colleagues Present FDA’s Psychedelic Drug Framework in NEJM

Psychedelic Philanthropy Is Entering Its Next Phase

Two New Zealand Psychiatrists Approved to Prescribe MDMA for PTSD

Pα+ Library: Psychedelic REMS

A Perspective on Providers: Scaling PAT in a Time of Therapist...

Making “Access” A Meaningful Part of Every Conversation about Psychedelic Therapy

Psychedelic Therapies: From Approvals to Access

Small Pharma Announces Update on Intellectual Property Portfolio with Two New...

Numinus Receives Clinical Trial Application Approval from Health Canada for Experiential...

PharmaTher Holdings Submits for FDA Orphan Drug Designation for Ketamine to...

Psyence and Eden Labs Announce Extraction and Product Development Collaboration

Silo Pharma Announces Stock Repurchase Program

FDA Grants Ehave Consent to Proceed With Its Clinical Study on...

Apex Labs Granted Approval for 294 Patient Take Home Psilocybin Clinical...

EDITOR PICKS

Approvals to Access: A Crude Schematic

Davis, Farchione and Colleagues Present FDA’s Psychedelic Drug Framework in NEJM

Psychedelic Philanthropy Is Entering Its Next Phase

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY